DONG-A ST CO.,LTD Logo

DONG-A ST CO.,LTD

Develops, manufactures, and markets drugs, medical devices, and diagnostics.

170900 | KO

Overview

Corporate Details

ISIN(s):
KR7170900005
LEI:
Country:
South Korea
Address:
서울 동대문구 용두동 138 ~255 천호대로 64, 서울

Description

Dong-A ST CO., LTD. is a pharmaceutical company focused on the research, development, manufacturing, and marketing of ethical drugs, medical devices, and diagnostics. The company's portfolio includes proprietary new drugs such as Stillen (gastritis), Zydena (erectile dysfunction), and Motilitone (functional dyspepsia). Operating from cGMP-compliant facilities, it exports a diverse range of products, including novel drugs, generics, and biopharmaceuticals, to global markets. The company maintains a strong commitment to innovative R&D, with a pipeline featuring first-in-class therapeutic candidates for metabolic diseases, including MASH (Metabolic dysfunction-associated steatohepatitis) and obesity, which are being advanced through a dedicated global R&D base.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2024-04-02 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 21.9 KB
2024-04-02 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 20.8 KB
2024-03-26 00:00
정기주주총회결과
Korean 29.7 KB
2024-03-26 00:00
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Korean 10.0 KB
2024-03-26 00:00
전환가액ㆍ신주인수권행사가액ㆍ교환가액의조정(안내공시)
Korean 13.9 KB
2024-03-18 00:00
감사보고서제출
Korean 21.6 KB
2024-03-18 00:00
사업보고서 (2023.12)
Korean 2.6 MB
2024-03-11 00:00
주주총회소집공고
Korean 182.1 KB
2024-03-11 00:00
의결권대리행사권유참고서류
Korean 150.7 KB
2024-03-07 00:00
기업설명회(IR)개최(안내공시)
Korean 6.5 KB
2024-02-23 00:00
투자설명서
Korean 2.7 MB
2024-02-23 00:00
주주총회소집결의
Korean 16.8 KB
2024-02-23 00:00
현금ㆍ현물배당결정
Korean 8.8 KB
2024-02-23 00:00
증권발행실적보고서
Korean 48.1 KB
2024-02-23 00:00
매출액또는손익구조30%(대규모법인은15%)이상변경
Korean 14.0 KB

Automate Your Workflow. Get a real-time feed of all DONG-A ST CO.,LTD filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for DONG-A ST CO.,LTD

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for DONG-A ST CO.,LTD via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

BIO-FD&C CO.,LTD. Logo
Develops active ingredients for cosmetics and pharma using a plant cell platform technology.
South Korea
251120
Biofrontera AG Logo
Biopharmaceutical firm specializing in photodynamic therapy for skin conditions.
Germany
B8F
Biofrontera Inc. Logo
A biopharmaceutical company commercializing products for dermatological conditions.
United States of America
BFRI
BioGaia Logo
A healthcare and biotechnology company developing clinically proven probiotic products.
Sweden
BIOG
BIOGEN INC. Logo
Biotechnology company developing therapies for neurological and neurodegenerative diseases.
United States of America
BIIB
Bio Green Med Solution, Inc. Logo
A diversified company in the biopharmaceutical and fire safety sectors.
United States of America
BGMS
BIOHARVEST SCIENCES INC. Logo
A biotech firm using a platform to grow plant cells for health and wellness products.
United States of America
BHST
Biohaven Ltd. Logo
Develops therapies for neuroscience, immunology, and oncology for unmet medical needs.
United States of America
BHVN
BioInvent International Logo
Develops novel, first-in-class immuno-modulatory antibodies for cancer therapy.
Sweden
BINV
BIOLIFE SOLUTIONS INC Logo
Manufactures biopreservation media and tools for cell and gene therapy markets.
United States of America
BLFS

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.